ARTICLE | Market Access
Patient death resurfaces safety concerns for Sarepta’s gene therapy
But it’s unclear that market access will be affected
March 19, 2025 12:32 AM UTC
The death of a patient treated with Sarepta’s gene therapy Elevidys resurfaces concerns about appropriate use of the Duchenne muscular dystrophy treatment.
Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) fell 27% on Tuesday, translating to a $2.7 billion loss in market cap, after the company reported that a 16-year-old boy with DMD died from acute liver failure after receiving Elevidys delandistrogene moxeparvovec. ...